サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：フィデューシャルマーカーの世界市場-2023-2030
市場調査レポート
商品コード
1217640

フィデューシャルマーカーの世界市場-2023-2030

Global Fiducial Markers Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
フィデューシャルマーカーの世界市場-2023-2030
出版日: 2023年02月14日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

フィデューシャルマーカーは、フィデューシャルとも呼ばれ、放射線治療を行うために細い針で患者の体内に挿入される小さな金属製のインプラントです。大きさは3mm程度です。マーカー自体に違和感はなく、患者さんは内部で感じることはありません。フィデューシャルの使用頻度が高いのは、前立腺がんの外部照射を受ける患者さんです。また、肺がん、頭頸部がんなどの軟部組織がんの治療にも使用されています。

市場力学

フィデューシャルマーカーの世界市場を牽引する主な要因は、がん罹患率の急増によるフィデューシャルメーカーの需要増、放射線に対する意識の高まり、医療画像診断の需要増、新興国における医療費増加などです。

がん罹患率の急増によるフィデューシャルメーカーの需要増が、市場の成長を牽引すると期待されています。

世界保健機関（WHO）によると、2022年には死亡者数の約6人に1人にあたる約1,000万人ががんで亡くなり、2020年には世界の死因のトップとなる見込みです。乳がん、肺がん、結腸がん、直腸がん、前立腺がんが最も多く見られるがんの種類です。タバコの使用、肥満度の高さ、飲酒、果物や野菜の摂取量の少なさ、運動不足などが、がんによる死亡の約3分の1を占めています。低・中所得国では、ヒトパピローマウイルス（HPV）や肝炎など、がんの原因となる感染症が、がん患者の30％を占めると考えられています。早期に発見し、適切な治療を行えば、多くの腫瘍は治癒が可能です。

米国国立がん研究所によると、米国では2020年に新たにがんと診断される患者数は180万6590人、がんによる死亡者数は60万6520人になると予想されています。最も多く見られるがんは、乳がん、肺がんおよび気管支がん、皮膚の黒色腫、膀胱がん、非ホジキンリンパ腫、腎臓および腎盂がん、子宮内膜がん、白血病、すい臓がん、甲状腺がん、肝臓がんです（2020年の推定患者数の多い順で掲載）。がん罹患率の上昇により、フィデューシャルプロデューサーが腫瘍を特定する可能性があることが市場を牽引しています。

製品に起因する合併症は、市場の成長を阻害すると予測されています。

フィデューシャルマーカーは、周囲の健康な組織へのダメージを最小限に抑えながら、腫瘍に最も効果的にドラッグデリバリーを行うことができるようになりました。フィデューシャルマーカーは、放射線治療において大きな利点がある一方で、その他のリスクもあります。

気胸と肺出血が最も頻繁に起こる副作用でした。FM埋め込みと生検サンプリングが同時に行われた場合、問題のリスクはより高くなることが判明しました。肺病変が問題の大部分を占め、肺病変に対するFM移植はすべてCTガイダンスのもとで行われました。自己限定性気胸、肺出血、喀血は重篤でない問題の一つでした。最も重篤な副作用は気胸で、医師の診察と入院が必要でした。

COVID-19の影響分析

強力なロックダウン手順と人の流れの制限により、COVID-19ウイルスの流行はフィデューシャルマーカー部門に最小限の影響しか与えていないです。現在のコロナウイルスの大流行は、ヘルスケアに害を及ぼしています。COVID-19の大流行は、フィデューシャルメーカーの市場だけでなく、世界のヘルスケアシステムにも大きな影響を及ぼしています。Cancer Connect 2020」の記事によると、ダナファーバーがん研究所の研究者は、最も頻度の高い6種類のがん（乳がん、大腸がん、肺がん、膵臓がん、胃がん、食道がん）の診断が、COVID-19の流行中に46%減少したことを発見しました。

さらに、疾病対策予防センター（CDC）をはじめとする多くの医療専門機関からは、リスクが利益を上回らない限り、選択的手術、がん検診、その他の健康予防サービスを遅らせること、COVID-19患者のケアに向けて病院のインフラを準備することが勧告されました。このようにCOVID-19の流行は、フィデューシャルの生産者の市場にダメージを与えました。しかし、時間の経過とともに状況は好転していくことが予想されます。大手ヘルスケア企業は、COVID-19のワクチンや治療薬の探索を強化しており、世界中の病院のインフラに多大な負担をかけています。それでも、がん治療の継続により、フィデューシャルマーカーの市場は堅調に推移しています。しかし、そのうちのいくつかは、予定が変更されたり、断念されたりしています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • がん罹患率の急増に伴うフィデューシャルメーカーの需要拡大
      • 放射線に対する意識の高まりが市場拡大に拍車をかける
    • 抑制要因
      • 製品に起因する合併症が市場成長の妨げになると予想されます。
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 製品構成別

  • ゴールドマーカー
  • ポリマーマーカー
  • カーボンマーカー
  • プラチナマーカー
  • リキッドマーカー
  • その他

第8章 アプリケーション別

  • 放射線治療
  • CT・CBCTスキャン
  • MRI・MEG検査
  • 内視鏡超音波検査
  • その他

第9章 設置場所別

  • 頭部・頸部
  • 乳房
  • 肺
  • 腹部
  • 前立腺
  • その他

第10章 エンドユーザー別

  • 病院
  • 外来外科クリニック
  • 専門クリニック
  • 研究機関

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Boston Scientific Corporation
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Medtronic Plc
  • Nanovi A/S
  • IBA Dosimetry
  • Roper Technologies Inc.
  • Guerbet SA
  • Eckert & Ziegler BEBIG S.A.
  • IZI Medical Products Inc.
  • Naslund Medical AB
  • MediTron SA.

第14章 フィデューシャルマーカーの世界市場-DataM

目次
Product Code: DMMI1830

Market Overview

The global fiducial markers market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

Fiducial markers, also referred to as fiducials, are tiny metal implants that are inserted into the body of a patient using a fine needle to direct radiation therapy. They are roughly 3 mm in size. The markers themselves are not uncomfortable, and the patient cannot feel them internally. Patients receiving external beam radiation therapy for prostate cancer are the ones who use fiducials the most frequently. They can, however, also be utilized to direct treatment for additional soft tissue cancer types, such as lung, head, and neck tumors.

Market Dynamics

The major factors driving the global fiducial markersmarket the rising demand for fiducial manufacturers due to a rapid rise in cancer incidences, the market's expansion is being further fuelled by the increased awareness of radiation, rising demand for medical imaging procedures and rising healthcare expenditure in emerging markets.

Rising demand for fiducial manufacturers due to a rapid rise in cancer incidences is expected to drive the market's growth.

According to World Health Organization, in 2022, nearly 10 million deaths, or nearly one in six deaths, will be caused by cancer 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. In low- and lower-middle-income nations, cancer-causing infections, including the human papillomavirus (HPV) and hepatitis, are thought to cause 30% of cancer cases. If caught early and appropriately treated, many tumors are curable.

And according to National Cancer Institute(U.S.A), in the U.S., there will likely be 1,806,590 new cases of cancer diagnosed in 2020, and there will also likely be 606,520 cancer-related deaths. The most prevalent cancers are breast cancer, lung and bronchus cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer (listed in descending order by estimated new cases in 2020). The market is driven by the possibility for the fiducial producers to identify the tumor due to the rise in cancer incidence.

The complications caused by the products are projected to impede the growth of the market.

Fiducial markers has made for the most effective drug delivery to tumors while causing the least amount of damage to surrounding healthy tissues. Fiducial markers have certain additional risks, although having a major benefit in radiation therapy procedures.

Pneumothoraces and pulmonary bleeding were the most frequent side effects. The risk of problems was found to be higher when FM implantation and biopsy sampling were done simultaneously. Lung lesions accounted for the majority of the issues, and all FM implantations for lung lesions were performed under CT guidance. Self-limiting pneumothoraces, pulmonary bleeding, and hemoptysis were among the less severe issues. The most severe side effect was a pneumothorax, which necessitated medical attention and hospitalization.

COVID-19 Impact Analysis

Due to strong lockdown procedures and a restricted flow of personnel, the COVID-19 virus epidemic has had a minimal impact on the fiducial markers sector. The current coronavirus pandemic has harmed healthcare. The COVID-19 pandemic has had a huge influence on the market for fiducial manufacturers as well as on the world's healthcare systems. According to an article in Cancer Connect 2020, researchers from the Dana Farber Cancer Institute found that the six most frequent cancer types-breast, colorectal, lung, pancreatic, gastric, and esophageal cancers-had a 46% decline in diagnoses during the COVID-19 pandemic.

Additionally, it was advised to delay elective surgeries, cancer screenings, and other health prevention services unless the risks outweighed the benefits and to prepare the hospital infrastructure for the care of COVID-19 patients by the Centers for Disease Control and Prevention (CDC) and many other medical professional organizations. The COVID-19 epidemic has thus damaged the market for fiducial producers. However, it is anticipated that things will get better with time. Major healthcare corporations are stepping up their attempts to find potential COVID-19 vaccines and medications, putting tremendous strain on hospital infrastructures worldwide. Despite this, ongoing cancer treatments have kept the market for fiducial markers strong. However, several of the procedures were rescheduled or abandoned.

Segment Analysis

The gold fiducial markers segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The gold fiducial markers segment is the highest market holder in the global fiducial markers market. Gold fiducial markers can also be combined with other metals like titanium, platinum, and nickel for increased effectiveness. For instance, these markers improve visibility in MRI scans when coupled with titanium stripes. Major businesses are increasing their R&D spending to create more efficient products. As an illustration, IBA Dosimetry GmbH introduced the Visicoil linear pure gold fiducial marker, a novel helical-shaped product with a hollow core that lowers the incidence of typical issues such as marker migration and artifacts.

Additionally, in June 2022, Nanovi reported that its liquid fiducial marker, BioXmark, has demonstrated in a clinical study to be technically possible to implant in stomach cancer patients to guide preoperative image-guided radiation therapy (IGRT). It can be difficult to accurately identify the treatment target on daily collected CBCT scans during preoperative IGRT of the stomach. Twelve (12) patients with stomach cancer participated in this clinical investigation from the Amsterdam University Medical Center. The study's objective was to evaluate the technological viability of implanting liquid marker (BioXmark) and gold marker (Visicoil) for preoperative stomach cancer IGRT guidance. The segment drives the market as a response.

Geographical Analysis

North America holds the largest market share in the global Fiducial Markers market.

North America dominates the global fiducial markers market primarily due to its large population, excellent medical infrastructure, and high-income levels. Due to factors such as the rising incidence of cancer, the presence of numerous major players, rising spending on research and development, increasing patient awareness and preference for radiotherapy, favorable reimbursement laws, and technological advancements, North America is anticipated to account for a sizeable portion of the global market for fiducial markers.

The American Association for Cancer Research reports that since the 1990s, the age-adjusted total cancer death rate in the U.S. has been consistently falling. The decrease between 1991 and 2019 means avoiding over 3.5 million cancer deaths. As of January 1, 2022, more than 18 million cancer survivors will live in the U.S., an increase of more than a million over the previous three years. The advancements in the fight against cancer have not benefited all American communities equally.

It'll also increase the need for disease treatment and grow the market. In North America, the U.S. holds the largest proportion of the market for fiducial markers. The Fiducial Markers Market in this area is also anticipated to benefit from cutting-edge radiation techniques, imaging modalities, and well-established healthcare infrastructure.

Competitive Landscape

The Fiducial Markers market is moderately competitive with local and global companies' presence such as Boston Scientific Corporation, Medtronic Plc, Nanovi A/S, IBA Dosimetry, Roper Technologies Inc., Guerbet SA, Eckert & Ziegler BEBIG S.A., IZI Medical Products Inc., Naslund Medical AB and MediTron SAand more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, first Prostate Cancer treatments use Nova Fiducial Markers announced by C4 Imaging. The first prostate cancer therapies using Nova, a multimodality fiducial marker created to improve the precision of cancer treatment, have been announced by C4 Imaging LLC.

Boston Scientific Corporation.

Overview:A medical technology company called Boston Scientific Corp. (Boston Scientific) is engaged in the development, production, and commercialization of devices for several interventional medical specialties. Electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain management, pulmonology, urology, and vascular surgery are among the specialties in which the company sells products. All across the world, Boston Scientific provides services to hospitals, clinics, outpatient facilities, and medical offices.

Product Portfolio:

LumiCoil PlatinumFiducial Markers:LumiCoil Platinum Fiducial Markers feature platinum construction designed for clear visibility in CT, X-Ray, EUS, CBCT, and MRI procedures. The use of fiducials may lead to more accurate targeting in delivery of radiation.

Theglobal Fiducial Markers marketreport would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising demand for fiducial manufacturers due to a rapid rise in cancer incidences
      • 4.1.1.2. The market's expansion is being further fueled by the increased awareness of radiation
    • 4.1.2. Restraints:
      • 4.1.2.1. Complications caused by the products are expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Composition

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 7.1.2. Market Attractiveness Index, By Product Composition
  • 7.2. Gold Markers
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 7.3. Polymer Markers
  • 7.4. Carbon Markers
  • 7.5. Platinum Markers
  • 7.6. Liquid Markers
  • 7.7. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Radiation Therapy
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. CT and CBCT Scans
  • 8.4. MRI and MEG Scans
  • 8.5. Endoscopic Ultrasound Scans
  • 8.6. Others

9. By Placement Locations

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 9.1.2. Market Attractiveness Index, By Placement Location
  • 9.2. Head and Neck
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Breast
  • 9.4. Lung
  • 9.5. Abdomen
  • 9.6. Prostate
  • 9.7. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 10.3. Ambulatory Surgical Clinics
  • 10.4. Specialty Clinics
  • 10.5. Research Institutions

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size AnalysisUS$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Boston Scientific Corporation
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Medtronic Plc
  • 13.3. Nanovi A/S
  • 13.4. IBA Dosimetry
  • 13.5. Roper Technologies Inc.
  • 13.6. Guerbet SA
  • 13.7. Eckert & Ziegler BEBIG S.A.
  • 13.8. IZI Medical Products Inc.
  • 13.9. Naslund Medical AB
  • 13.10. MediTron SA.

LIST NOT EXHAUSTIVE

14. Global Fiducial Markers Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us